Diulactone is commonly used to help with several complex conditions. The medicine is considered relevant in contexts involving symptoms related to systemic imbalance, symptoms that create noticeable physiological strain, and specific hormonal disorders.

Diulactone: Core Therapeutic Uses

Diulactone helps address symptom clusters that may become intense or disruptive, such as swelling (edema) in chronic conditions, symptoms related to systemic imbalance, and symptoms that create noticeable physiological strain (high blood pressure). It is applied in scenarios where additional management of discomfort is required, including conditions like chronic heart failure, hepatic cirrhosis (which causes ascites), resistant hypertension, and conditions marked by excessive aldosterone production.

“This supportive action may assist with managing symptoms related to heightened physiological activity, which contributes to easing the overall symptom load.”

For patients experiencing these conditions characterized by periods of heightened symptoms, the treatment provides support that helps ease the overall symptom burden. Furthermore, in adult females, it is commonly applied to help moderate distressing symptoms like persistent acne and excessive hair growth (hirsutism).

Quick Fact: Relief for Volume Overload
Focus: Used for managing symptoms related to physical discomfort (fluid retention and swelling).
Key Benefit: Assists with maintaining functional stability and helps improve day-to-day comfort during symptomatic periods.
Context: Applied in conditions like heart failure and cirrhosis.

Regulatory References

1. National Institutes of Health (NIH) DailyMed overview

Diulactone (Spironolactone) is a prescription medicine with specific eligibility rules established by regulatory bodies, defining which populations may use the drug and which are strictly excluded.

Populations Who Must Not Use Diulactone

The medicine is formally contraindicated and must not be used by patients with the following conditions, as stated in the official labeling:

• Hyperkalemia (high potassium levels in the blood).
• Addison’s disease (chronic adrenal insufficiency).
• Acute renal insufficiency, significant renal compromise, or anuria (severe kidney impairment).
• Hypersensitivity (known allergy) to Spironolactone or its components.
• Concomitant use with the aldosterone antagonist eplerenone.

Populations Requiring Special Consideration

Category	Official Regulatory Status
Older Adults (Geriatric)	Require caution and closer monitoring due to potential age-related kidney function issues.
Renal / Hepatic Impairment	Requires caution and frequent monitoring of electrolytes; use is conditional on the severity of impairment.
Pregnancy	Use is not recommended unless the benefit is determined to justify the documented potential risk to the fetus.
Pediatric Patients	Safety and effectiveness have not been established in the pediatric population (U.S. labeling).

These official statements define the drug's population eligibility, primarily based on the risk of dangerously affecting electrolyte and organ function balance.

Interactions with other medicines and products

The interaction profile for Diulactone (Spironolactone) is primarily defined by its effects on potassium balance and the systemic exposure of certain co-administered substances. All documented statements are sourced from government regulatory labeling.

Interaction Type	Interacting Agents / Classes	Documented Outcome
Formal Contraindication	Eplerenone (Aldosterone Antagonist)	Contraindicated due to significantly increased risk of severe hyperkalemia (high serum potassium levels).
Pharmacodynamic Risk	ACE Inhibitors, ARBs, Potassium Supplements, Heparin, LMWH, other Potassium-Sparing Diuretics, Trimethoprim	Additive effects that elevate the risk of hyperkalemia.
Pharmacokinetic Effect	Food Intake	Food increases the bioavailability of unmetabolized Diulactone by almost 100%, altering systemic exposure.
Exposure Modification	Digoxin	Diulactone increases the plasma half-life of Digoxin, potentially raising Digoxin exposure.
Efficacy Attenuation	NSAIDs (e.g., Indomethacin, Aspirin)	May attenuate (reduce) the natriuretic (diuretic) efficacy of Diulactone.

The regulatory structure emphasizes that agents which increase potassium retention, such as ACE Inhibitors and ARBs, require careful monitoring when combined with Diulactone due to a heightened risk of hyperkalemia. This risk is officially noted to be increased in specific populations, including elderly patients and those with impaired renal function. Cholestyramine has also been reported to cause hyperkalemic metabolic acidosis when co-administered. The documented food interaction indicates that meals substantially modify the drug's absorption, a key pharmacokinetic constraint.

Diulactone, chemically known as prorenone, functions as a mineralocorticoid receptor antagonist. Its primary target is the mineralocorticoid receptor (MR), particularly in the epithelial cells of the distal convoluted tubule and collecting duct of the renal nephron.

The molecule competitively inhibits the binding of the endogenous hormone aldosterone to the intracellular MR. This antagonism prevents the aldosterone-MR complex from translocating to the nucleus and binding to DNA response elements. Consequently, this inhibits the MR-mediated genomic pathway, which normally upregulates the transcription of genes encoding proteins critical for sodium and potassium transport, such as the Epithelial Sodium Channel (ENaC) and the basolateral Na^+/ K^+-ATPase.

The resulting intracellular consequence is the decreased synthesis and membrane insertion of these transport proteins. This reduction in functional ENaC and Na^+/ K^+-ATPase activity in the principal cells leads to decreased sodium reabsorption from the lumen and reduced potassium secretion into the lumen. The system-level physiological consequence is the modulation of water and electrolyte balance, specifically increased urinary sodium and water excretion and decreased urinary potassium excretion.

How Diulactone is Used

Diulactone, containing the active substance spironolactone, is administered exclusively via the oral route, available as both a solid tablet and an oral suspension for systemic delivery. The official instructions for use establish precise, standardized dosing protocols tailored to specific clinical scenarios.

Usage involves taking the medicine with food or a meal to optimize the consistency of absorption, and patients are directed to maintain this timing consistently each day. If the oral suspension form is utilized, the container must be shaken thoroughly before measuring the dose to ensure proper distribution of the active substance.

Dosing and Scheduling Principles

Administration frequency follows either a once daily or a divided doses pattern, depending on the regimen and total daily dose prescribed. The official labeled dosage can range from 25 mg up to 400 mg per day, with the maximum dose being reserved for complex edematous states. For chronic management, such as in essential hypertension, typical doses range from 25 mg to 100 mg daily. Dose adjustments for all conditions are managed gradually over time; for example, assessing the effect in hypertension requires a minimum duration of two weeks at a given dose before modification is considered.

Population-Specific Administration

Regulatory documents provide specific administration frameworks for certain patient groups. For older adults, official guidance directs initiating treatment with the lowest possible dose and increasing it in small, gradual steps. Treatment for pediatric patients is based on body weight (typically 1 mg/kg to 3 mg/kg daily) and must be conducted under the direction of a specialist. If a dose is missed, patients are advised to take it as soon as possible, unless it is close to the next scheduled dose, in which case the missed dose should be skipped; no attempt should be made to double the dose.

Research Evidence / Overview of Studies for Diulactone

---

Evidence for Use in Chronic Heart Failure

Research for Diulactone in chronic heart failure with reduced heart function includes major, long-term Randomized Controlled Trials (RCTs) and comprehensive meta-analyses. These studies was studied for their potential role when used alongside other standard heart failure medications. Researchers primarily examined critical outcomes such as patient survival (all-cause mortality) and the frequency of patient hospitalization for cardiac reasons, as well as objective measures of patient functional status.

The long-term trials were designed to measure patient survival (mortality) and the frequency of patient hospitalization. Changes in these rates were observed alongside measurements of patient functional status. Regulatory summaries outline these outcomes as part of the context for its use in this condition. However, research describes that the foundational studies providing this context primarily included white populations. This means that data for certain groups remain insufficient to fully characterize how the findings apply across all different races and ethnicities.

---

Evidence for Use in Resistant High Blood Pressure

The evidence base for Diulactone in cases of resistant high blood pressure includes systematic reviews and trials where the medicine was added to a patient’s existing regimen. Studies included populations whose blood pressure was observed in high ranges despite already taking three or more different classes of blood pressure medications. The key measurements studies monitored included blood pressure readings taken in the clinic and continuous readings taken over a full 24-hour period.

Trials consistently reported measurements of blood pressure changes when the compound was studied as an add-on to existing treatments. However, evidence quality varies across studies, and findings were mixed regarding the exact degree of change, which is partially due to the high variability (heterogeneity) in the other medications patients were taking. Furthermore, these follow-up durations were limited, typically lasting only a few months, meaning long-term effects are not fully established for this specific application.

---

Evidence for Use in Fluid Management (Edema/Ascites)

Diulactone was studied for its role in fluid management based on historical clinical trials and regulatory data. Studies focused on measuring changes in fluid volume (diuresis), physical measurements of swelling (edema/ascites), and objective markers of electrolyte balance (like potassium). The populations was observed in included patients experiencing fluid accumulation as a consequence of underlying serious conditions such as liver cirrhosis (which causes ascites) or certain types of severe kidney disease (nephrotic syndrome).

Evidence contributes to understanding symptom patterns related to fluid imbalance, and this use is historically recognized in regulatory contexts. However, most contemporary, large-scale research is now structured to focus on cardiovascular outcomes, meaning comparative evidence is lacking for studies that only focus on fluid management outside of that context.

---

Research Gaps and Areas of Uncertainty

Multiple research gaps are still emerging across the evidence base. For instance, the comparative evidence is lacking in large-scale trials that directly compare Diulactone to all other fluid-regulating medications. For the specialized use in persistent acne and resistant high blood pressure, long-term effects are not fully established due to limited follow-up durations. Finally, in heart failure with preserved ejection fraction, certainty remains low on the overall effect because the main clinical trials reported mixed findings on their primary endpoints.

Key Studies & References Label: SPIRONOLACTONE tablet (Indications and Usage for Heart Failure, Hypertension, and Edematous Conditions)

Common questions about Diulactone (FAQ)

---

Q: Is Diulactone safe to use during pregnancy or breastfeeding?

Regulatory documents advise against the use of Diulactone during pregnancy, as animal studies have indicated potential effects on fetal sex differentiation. For breastfeeding, official information confirms that the drug and its active metabolite are excreted into human milk. Therefore, decisions regarding continuing the drug or continuing nursing are managed by the prescribing healthcare provider.

---

Q: Are there any official restrictions on alcohol consumption with Diulactone?

Official prescribing information indicates that alcohol may have additive effects when taken with Diulactone. Alcohol consumption is associated with a heightened risk of experiencing low blood pressure. This combination may also increase the likelihood of experiencing side effects such as dizziness, lightheadedness, or fainting.

---

Q: Is it safe to drive or operate machinery while taking Diulactone?

Official guidance suggests caution regarding activities requiring alertness, as regulatory documents mention that this medication may cause dizziness or drowsiness. Patients are generally informed to avoid driving or operating hazardous machinery initially. They are informed to wait until they are aware of the drug’s effect before engaging in these tasks.

---

Q: What is the shelf life of Diulactone tablets?

Official drug labeling specifies proper storage conditions to maintain the quality of the medication. Diulactone should be stored at Controlled Room Temperature, which typically falls between 59°F (15°C) and 86°F (30°C). Official product information states that the tablets should be protected from exposure to light.

---

Q: How is Diulactone removed from the body?

According to the pharmacokinetics sections of regulatory documents, the active substance spironolactone is rapidly and extensively processed after ingestion. The components of the drug are processed and then primarily eliminated from the body in the urine. A secondary route of elimination is via the bile.

---

Q: Is Diulactone available over the counter in any country?

Official drug information confirms that Diulactone (spironolactone) is exclusively a prescription-only (Rx) medication. It is not available for purchase without a prescription from a licensed healthcare provider in any country covered by the official regulatory documents.

---

Q: Does Diulactone cause weight changes?

Official labeling and regulatory documents do not list weight gain or weight loss as a common or adverse effect of this medication. However, because Diulactone works to increase the excretion of sodium and water (a diuretic effect), fluid loss is the expected result. Changes in weight related to fluid balance may be experienced by some individuals.

---

Q: Is there a generic version of Diulactone?

Yes, according to official regulatory information, the active substance in Diulactone is spironolactone. Spironolactone is listed by the FDA under its generic name, confirming its availability as a generic product alongside brand names. This is common in the pharmaceutical market, where many medications are available in both brand-name and generic forms.

---

Q: Are there warnings about sun exposure while using Diulactone?

The official regulatory safety information for Diulactone does not universally include a general warning about photosensitivity or sun exposure. However, the labeling does include warnings about rare, serious skin reactions, such as Stevens-Johnson syndrome (SJS) and Toxic Epidermal Necrolysis (TEN). Patients are generally advised to be aware of any changes in their skin appearance while taking medication.

Official Storage and Disposal Instructions for Diulactone (Spironolactone)

Diulactone tablets must be stored at Controlled Room Temperature, which is officially 20 to 25 C (68 to 77 F). The medicine must be protected from light and kept from freezing.

Storage Requirements

Condition	Requirement
Temperature	Controlled Room Temperature (20 to 25 C)
Container	Tightly closed, light-resistant container
Safety	Keep out of the reach of children

Disposal Procedures

Official guidance states that Diulactone should not be flushed down the sink or toilet. The preferred method for discarding expired or unused tablets is to return them through an authorized drug take-back program. If a program is unavailable, the medicine may be disposed of in household trash only after being mixed with an unappealing substance and sealed in a container.